Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 1
1995 2
1998 1
1999 2
2000 1
2001 1
2002 3
2003 2
2004 4
2005 2
2006 4
2007 2
2008 1
2009 1
2010 2
2011 7
2012 4
2013 3
2014 3
2016 1
2017 1
2018 1
2019 3
2020 8
2021 6
2022 4
2023 5
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease.
Bellver-Sanchis A, Valle-Garcia D, Barbaraci C, Romero-Becerra F, Singh RK, Jarne-Ferrer J, Vasilopoulou F, Irisarri A, Martínez-Fernández C, Fafián-Labora JA, Arufe MC, Wüst C, Castellanos A, Soto D, Casals N, Fadó R, Pocock JM, Navarro G, Val C, Brea J, Loza MI, Lleó A, Fortea J, Alcolea D, Perez-Bosque A, Miró L, Pérez B, Rashid S, Ali M, Saqib M, Lí Carbó M, Guerrero A, Vázquez S, Choudhary BS, Dai S, Escolano C, Franco R, Pallàs M, Griñán-Ferré C. Bellver-Sanchis A, et al. Among authors: escolano c. Mol Ther. 2025 Dec 24:S1525-0016(25)01061-5. doi: 10.1016/j.ymthe.2025.12.038. Online ahead of print. Mol Ther. 2025. PMID: 41445192 Free article.
Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I2 Receptor Ligands with Anti-Alzheimer and Analgesic Properties.
Bagán A, López-Ruiz A, Abás S, Ruiz-Cantero MC, Vasilopoulou F, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Muguruza C, Diez-Alarcia R, Callado LF, Entrena JM, Cobos EJ, Pérez B, Morales-García JA, Molins E, De Jonghe S, Daelemans D, Brea J, Val C, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Díaz C, Fernández-Godino R, Genilloud O, Beljkaš M, Oljačić S, Nikolic K, Escolano C. Bagán A, et al. Among authors: escolano c. J Med Chem. 2025 Feb 13;68(3):2551-2573. doi: 10.1021/acs.jmedchem.4c01644. Epub 2025 Jan 17. J Med Chem. 2025. PMID: 39818939 Free PMC article.
Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist).
Ros T, Enriquez-Geppert S, Zotev V, Young KD, Wood G, Whitfield-Gabrieli S, Wan F, Vuilleumier P, Vialatte F, Van De Ville D, Todder D, Surmeli T, Sulzer JS, Strehl U, Sterman MB, Steiner NJ, Sorger B, Soekadar SR, Sitaram R, Sherlin LH, Schönenberg M, Scharnowski F, Schabus M, Rubia K, Rosa A, Reiner M, Pineda JA, Paret C, Ossadtchi A, Nicholson AA, Nan W, Minguez J, Micoulaud-Franchi JA, Mehler DMA, Lührs M, Lubar J, Lotte F, Linden DEJ, Lewis-Peacock JA, Lebedev MA, Lanius RA, Kübler A, Kranczioch C, Koush Y, Konicar L, Kohl SH, Kober SE, Klados MA, Jeunet C, Janssen TWP, Huster RJ, Hoedlmoser K, Hirshberg LM, Heunis S, Hendler T, Hampson M, Guggisberg AG, Guggenberger R, Gruzelier JH, Göbel RW, Gninenko N, Gharabaghi A, Frewen P, Fovet T, Fernández T, Escolano C, Ehlis AC, Drechsler R, Christopher deCharms R, Debener S, De Ridder D, Davelaar EJ, Congedo M, Cavazza M, Breteler MHM, Brandeis D, Bodurka J, Birbaumer N, Bazanova OM, Barth B, Bamidis PD, Auer T, Arns M, Thibault RT. Ros T, et al. Among authors: escolano c. Brain. 2020 Jun 1;143(6):1674-1685. doi: 10.1093/brain/awaa009. Brain. 2020. PMID: 32176800 Free PMC article.
Design and Synthesis of AMPK Activators and GDF15 Inducers.
Zhang M, Bagán A, Martínez D, Barroso E, Palomer X, Vázquez S, Escolano C, Vázquez-Carrera M. Zhang M, et al. Among authors: escolano c. Molecules. 2023 Jul 17;28(14):5468. doi: 10.3390/molecules28145468. Molecules. 2023. PMID: 37513338 Free PMC article.
Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease.
Bagán A, Rodriguez-Arévalo S, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Brocos-Mosquera I, Callado LF, Morales-García JA, Pérez B, Diaz C, Fernández-Godino R, Genilloud O, Beljkas M, Oljacic S, Nikolic K, Escolano C. Bagán A, et al. Among authors: escolano c. Pharmaceutics. 2023 Sep 25;15(10):2381. doi: 10.3390/pharmaceutics15102381. Pharmaceutics. 2023. PMID: 37896141 Free PMC article.
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease.
Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Abás S, et al. Among authors: escolano c. J Med Chem. 2020 Apr 9;63(7):3610-3633. doi: 10.1021/acs.jmedchem.9b02080. Epub 2020 Mar 19. J Med Chem. 2020. PMID: 32150414
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease.
Griñán-Ferré C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol-Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, Pérez B, Loza MI, Brea J, Morisseau C, Hammock BD, Vázquez S, Pallàs M, Galdeano C. Griñán-Ferré C, et al. Among authors: escolano c. Neurotherapeutics. 2020 Oct;17(4):1825-1835. doi: 10.1007/s13311-020-00854-1. Neurotherapeutics. 2020. PMID: 32488482 Free PMC article.
81 results